Indigo is pleased to announce that the first patient has now been enrolled into ‘Action-1”, the company’s prospective, non-randomized, interventional, multi-center data collection study.

The study collects venous blood samples in male T1D patients to evaluate the behavior of different biomarkers (beta-hydroxybutyrate, lactate, glucose) during and after morning Aerobic (60% of VO2 max) and Symptom Limited Maximal Exercise Test.

Action-1 intends to study 24 patients across 3 sites in Europe (Belgium – France – Italy).

Data will be collected at baseline and one additional time 1 to 6 weeks after the Baseline assessment.